Varian Medical Systems Inc

Varian Medical Systems — Q3 FY2020 Earnings Presentation

36 slides from Varian Medical Systems's earnings presentation, Aug 3, 2020

  1. Slide 1: Third Quarter Fiscal Year 2020

    Third Quarter Fiscal Year 2020 August 2, 2020 Investor Relations

  2. Slide 2: Forward-Looking Statements

    This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. S

  3. Slide 3: Agenda

    Agenda Q3 FY 2020 earnings 1. Third Quarter Overview 2. Total Company Performance 3. Segment Performance 4. Appendix VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY

  4. Slide 4: Third Quarter Overview

    Third Quarter Overview ee

  5. Slide 5: Q3 FY 2020 key financial metrics

    Q3 FY 2020 key financial metrics • Operating performance reflects a full quarter of COVID-19 impact across all geographies • Orders and revenues continue to be stressed due to customer capital constraints, site access challenges, and delayed pre-installation activities • Maintaining fiscal disciplin

  6. Slide 6: Long-term growth and value creation strategy

    Long-term growth and value creation strategy Focusing on these Strategic enablers will deliver core opportunities business growth, global expansion and new Global Leader in Multidisciplinary Cancer Care Solutions Global Leader in Radiation Therapy 6 Innovate in radiation therapy Leverage artificial

  7. Slide 7: Executing on long-term growth strategy

    Executing on long-term growth strategy Technologies Improve Financial, Operational, and Capital Efficiency 7 (1) Based on company estimates, industry reports and data as of April 2020 Innovate Leverage Grow in Radiation Therapy Artificial Intelligence, Machine Learning, and Cloud Solutions Emerging

  8. Slide 8: Varian strengthened its global leadership in radiation therapy

    Varian Installed linac net installed base base growth 8,599 (+2%) Q3 FY19 Note: Net installed base is representative of total installed base net of replacements in the period. Q3 FY20 8 8,412 +187 Varian strengthened its global leadership in radiation therapy • Net installed base grew +2% or 187 uni

  9. Slide 9: Key wins

    Key wins GenesisCare 3 Halcyon, 2 Edge, and 1 Ethos Hartford HealthCare 5 TrueBeams Germany 1 Ethos Italy 1 TrueBeam Korea 1 VitalBeam Japan 1 Edge Ochsner Foundation Hospital 7 TrueBeams France 4 Halcyon Southern Medical Capital Radiosurgery Centers India – Tata Trust 1 TrueBeam Israel 1 Halcyon Ch

  10. Slide 10: Total Company Performance

    Total Company Performance OO

  11. Slide 11: Total company results (GAAP)

    Total company results (GAAP) Key P&L financial metrics VARIAN Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders, all growth rates are in dollars and year on year, and basis points (bps) are rounded to the nearest tens. (1) TTM EPS is defined as the sum of last four quarters’ reported E

  12. Slide 12: Total company results (non-GAAP)

    Total company results (non-GAAP) Key P&L financial metrics VARIAN Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders, all growth rates are in dollars and year on year, and basis points (bps) are rounded to the nearest tens. (1) Excludes the portion of amortization of intangible assets a

  13. Slide 13: Strong financial position

    Strong financial position Key balance sheet and cash flow metrics Cash & Cash Equivalents ($M) FY19 FY19 FY20 FY20 FY20 T +$180M Y/Y 13 (1) \Leverage ratio as defined in the amended Credit Agreement, dated November 1, 2019. +48% Y/Y $800 $700 $600 $500 $400 Q3Q4Q1Q2Q3 FY19FY19FY20FY20FY20 Cash Flow

  14. Slide 14: Revenue visibility drivers

    Revenue visibility drivers Services revenue mix & product backlog 100% $3,500 $3,000 $2,500 $2,000 50% $1,500 $1,000 $500 $-0% FY05 FY10 FY15 FY20 TTM FY05 FY10 FY15 FY20 TTM Product % of Total Revenues Service % of Total Revenues Oncology Systems Backlog ($M) Note: Excludes Varex; ASC 605 to 606 re

  15. Slide 15: Capital allocation priorities

    Capital allocation priorities Evaluating investment opportunities with discipline necessary in this environment Long-term value creation strategy that includes balancing growth, profitability and liquidity Returning cash to shareholders over time 15 •Temporarily paused share repurchase program to pr

  16. Slide 16: Segment Performance

    Segment Performance Oe

  17. Slide 17: Oncology Systems segment (GAAP) key financial metrics

    Oncology Key financial Systems metrics segment (GAAP) VARIAN Operating Earnings $101 (32%) Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders and all growth rates are in dollars and year on year, and basis points (bps) are rounded to the nearest tens. (1) Operating earnings includes an

  18. Slide 18: Oncology Systems gross orders by geography

    Oncology Systems gross orders by geography APAC AMERICAS +4% Q3 Y/Y (+4% cc) -8% Q3 Y/Y1 (-8% cc) -1% TTM (-1% cc) Y/Y +2% TTM Y/Y1 (+3% cc) (1) In North America, Q3 orders growth of -6% and TTM orders growth of +2% EMEA -32% Q3 Y/Y (-30% cc) -1% TTM Y/Y (+1% cc) 18

  19. Slide 19: Proton Solutions segment (GAAP) key financial metrics

    Proton Solutions segment (GAAP) Key financial metrics VARIAN Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders and all growth rates are in dollars and year on year, and basis points (bps) are rounded to the nearest tens. N/M: not meaningful. (1) Operating earnings includes an allocatio

  20. Slide 20: ProBeam proton therapy system sites

    ProBeam proton therapy system sites Sites Operational Centers Centers Under Development Rooms1 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 20 28 80 Total Rooms ProBeam 40 Operational 13 Operational Sites

  21. Slide 21: Other segment (GAAP) key financial metrics

    Other segment (GAAP) Key financial metrics VARIAN Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders and all growth rates are in dollars and year on year, and basis points (bps) are rounded to the nearest tens. N/M: not meaningful. (1) Operating earnings includes an allocation of corpor

  22. Slide 22: In summary, we are…

    In summary, we are… Global leader in radiation therapy …Driving toward ourvision Growing our net installed base driving future recurring software and services revenues of a fear world without Expanding into high growth, high margin businesses of cancer Winning in emerging markets with our strong val

  23. Slide 23: Appendix

    Appendix

  24. Slide 24: Machine utilization trends

    Machine utilization trends 117% 100% 100% 99% Note: Based on internal data, as of week of July 20, 2020 24 New Year UNITED STATES New Year CHINA • Cancer treatment is not considered an elective procedure • Volume impact from COVID-19 has varied, but has stayed above 95% across U.S., EMEA and APAC

  25. Slide 25: Non-GAAP disclosure

    Non-GAAP disclosure Discussion of Non-GAAP Financial Measures This presentation includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: organic revenue growth, non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per

  26. Slide 26: Organic revenue growth reconciliation

    Organic revenue growth reconciliation Acquisitions Foreign Exchange Total Revenues $825.8 $694.3 (16)% 2% 1% (19)% Acquisitions Foreign Exchange Total Revenues $779.4 $794.5 2 % 4% (1) % (1)% Acquisitions Foreign Exchange Total Revenues $741.0 $828.9 12 % 5% (1) % 8 % $M1Q FY191Q FY20Percent ChangeI

  27. Slide 27: GAAP to non-GAAP reconciliation

    GAAP to non-GAAP reconciliation THE FOLLOWING TABLE RECONCILES GAAP AND NON-GAAP FINANCIAL MEASURES 3Q FY19 4Q FY19 1Q FY20 2Q FY20 3Q FY20 Dollars and shares in millions, except per share amounts Non-GAAP adjustments Amortization of intangible assets and inventory step-up (1) Restructuring charges

  28. Slide 28: Total revenues by sales classification

    Total revenues by sales classification CC – Constant currency 28 $M3Q FY194Q FY191Q FY202Q FY203Q FY20 Product revenues$461.3$492.1$421.0$407.3$320.2 Y/Y26 %10 %5 %(5)%(31)% Service revenues$364.5$386.8$407.9$387.2$374.1 Y/Y6 %9 %20 %11 %3 % Total revenues$825.8$878.9$828.9$794.5$694.3 Y/Y16 %10 %12

  29. Slide 29: Total revenues by product type

    Total revenues by product type Total revenues Y/Y - CC $825.8 $878.9 $828.9 $794.5 $694.3 (16)% (15)% (1) Includes software support agreements that are recorded in revenues from service, and software licenses that are recorded in revenues from product, in the Condensed Consolidated Statements of Ear

  30. Slide 30: Total revenues by region

    Total revenues by region Total revenues $825.8 $878.9 $828.9 $794.5 $694.3 Y/Y 16 % 10 % 12 % 2 % (16)% Y/Y – CC 19 % 11 % 13 % 3 % (15)% CC – Constant currency 30 $M3Q FY194QFY191Q FY202Q FY203Q FY20 Americas revenues$401.2$404.5$402.2$387.9$337.5 Y/Y17 %2 %15 %4 %(16)% Y/Y – CC17 %2 %15 %5 %(16)%

  31. Slide 31: Total Oncology Systems revenues by sales classification

    Total Oncology Systems revenues by sales classification Total revenues $792.9 $819.6 $782.4 $760.5 $654.5 Y/Y 19 % 8 % 11 % 2 % (17)% Y/Y – CC 22 % 9 % 12 % 3 % (17)% CC – Constant currency 31 Product as a percentage of total Oncology Systems revenues55 %54 %49 %50 %44 % Service as a percentage of t

  32. Slide 32: Total Oncology Systems revenues by region

    Total Oncology Systems revenues by region Total revenues $792.9 $819.6 $782.4 $760.5 $654.5 Y/Y 19 % 8 % 11 % 2 % (17)% Y/Y – CC 22 % 9 % 12 % 3 % (17)% CC – Constant currency 32 $M3Q FY194Q FY191Q FY202Q FY203Q FY20 Americas revenues$385.6$377.8$378.9$369.7$318.1 Y/Y19 %2 %15 %4 %(18)% Y/Y – CC20 %

  33. Slide 33: Total Proton Solutions revenues by sales classification

    Total Proton Solutions revenues by sales classification Y/Y (26)% (9)% (28)% (32)% 6 % 33 Proton Solutions revenues as a percentage of total revenues4 %7 %3 %3 %5 % $M3Q FY194Q FY191Q FY202Q FY203Q FY20 Product revenues$25.5$35.3$20.1$14.6$23.1 Y/Y(33)%(19)%(40)%(48)%(9)% Service revenues$5.4$6.6$7.

  34. Slide 34: Oncology Systems gross orders by region

    Oncology Systems gross orders by region CC – Constant currency 34 $M3Q FY194Q FY191Q FY202Q FY203Q FY20 Americas orders$357.4$559.0$359.5$355.4$329.1 Y/Y(1)%11 %7 %(3)%(8)% Y/Y – CC(1)%11 %7 %(3)%(8)% EMEA orders$281.1$395.9$236.7$259.3$191.1 Y/Y8 %10 %8 %11 %(32)% Y/Y – CC13 %12 %11 %13 %(30)% APAC

  35. Slide 35: Condensed consolidated statements of cash flows

    Condensed consolidated statements of cash flows $M 3Q FY19 4Q FY19 1Q FY20 2Q FY20 3Q FY20 Net cash provided by (used in) Operating Activities Net earnings Share-based compensation expense Depreciation Amortization of intangible assets and inventory step-up Changes in assets and liabilities, net Oth

  36. Slide 36: Our promise: People powering victories

    Our promise People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer. W

Varian Medical Systems — Q3 FY2020 Earnings Presentation on 6ix